Brief: Orgenesis Achieves Multiple Ranpirnase Development Milestones
06/07/2021 12:18
July 6 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS ACHIEVES MULTIPLE RANPIRNASE DEVELOPMENT
MILESTONES
* ORGENESIS - LICENSING PARTNER, OKOGEN, INC., PRESENTED
POSITIVE
INTERIM PHASE 2 CLINICAL TRIAL RESULTS OF OKG-0301 IN ACUTE
ADENOVIRAL CONJUNCTIVITIS
Source text for Eikon: ID:nGNX4tHxv1
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules